BT PHARMA is an emerging biopharmaceutical company focused on developing innovative therapeutic vaccines for the treatment of cervical cancer and associated neoplasia caused by human papillomavirus (HPV) . The company's lead candidate therapeutic vaccine, ProCervix® is scheduled to receive approval for its first clinical trials in 2009. BT PHARMA plans to develop ProCervix® to proof of concept stage.
The company was created in October 2001 and is based in Labège (Toulouse), France.
BT Pharma appoints Thierry Hercend as President of its Supervisory Board
- 10/08/2008
Prof. Thierry Hercend, well-known for his work in Oncology R & D, brings vast experience in management of biopharmaceutical development to BT Pharma
BT Pharma nomme le Pr. Thierry Hercend président de son Conseil de Surveillance
- 10/08/2008
Professionnel de la R & D en oncologie, le Pr. Thierry Hercend apporte une grande expérience de gestion du développement biopharmaceutique à BT Pharma
BT Pharma lève 2.8 millions d'Euros
- 09/22/2008
BT Pharma, une société de biotechnologie développant de nouveaux vaccins thérapeutiques contre les maladies et les cancers associés à HPV a le plaisir d'annoncer la clôture d'un financement en capital de 2 825 000 euros.